The filing is a routine investor presentation update with no new financial data. The key catalyst to watch is the IND filing for C-006 in June 2026 and subsequent Phase 3 enrollment updates. The refined trial design targeting restrictive lung disease patients may reduce regulatory risk but does not change the binary outcome risk of the Phase 3 readout.
Price Chart
Executive Summary
aTyr Pharma filed an 8-K with an investor presentation detailing plans for a new Phase 3 study (C-006) of efzofitimod in pulmonary sarcoidosis, following a Type C meeting with the FDA. The presentation highlights a refined study design focusing on restrictive lung disease patients with FVC as the primary endpoint, and reports ~$68.3M in cash as of March 31, 2026. The filing is a routine business update with no new financial results or material definitive agreements.
Key Facts
- Planned Phase 3 study (C-006) of efzofitimod in pulmonary sarcoidosis with FVC as primary endpoint, targeting restrictive lung disease patients.
- FDA Type C meeting outcome: FDA supported FVC and KSQ-L as clinically meaningful endpoints; company concluded FVC is more appropriate for C-006.
- Company plans to file IND for C-006 in June 2026.
- EFZO-FIT trial (largest interventional pulmonary sarcoidosis trial) did not meet primary endpoint but showed trends in steroid reduction and QoL improvements.
- Cash, restricted cash, cash equivalents and available-for-sale investments of ~$68.3M as of March 31, 2026.
- EFZO-CONNECT Phase 2 study in SSc-ILD ongoing; enrollment completion expected in 1H 2026.
- Preclinical candidate ATYR0101 for fibrosis undergoing IND-enabling studies.
Financial Impact
No new financial results reported. Cash position of ~$68.3M as of March 31, 2026.
Risk Factors
- EFZO-FIT missed its primary endpoint; Phase 3 success is not assured.
- Cash runway of ~$68.3M may require additional financing to complete the Phase 3 program.
- Regulatory path for FVC as primary endpoint in pulmonary sarcoidosis is not fully established.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001339970-26-000036 |
| Document: atyr-ex99_1.htm | 0001339970-26-000036 |
| Document: 0001339970-26-000036-index-headers.html | 0001339970-26-000036 |
| Document: 0001339970-26-000036-index.html | 0001339970-26-000036 |
| Document: 0001339970-26-000036.txt | 0001339970-26-000036 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $0.1717 $0.1534 | ▼ −10.66% | ▼ −10.51% | $0.1530 (−10.89%) |
Oct 7, 2026 20d ago | SC 13G/A | $0.2783 $0.1833 | ▼ −34.14% | ▼ −33.16% | $0.1530 (−45.02%) |
Sep 22, 2026 4w ago | Institutional Cluster | $0.3564 $0.3077 | ▲ +13.66% | ▲ +12.48% | $0.1530 (+57.07%) |
Aug 7, 2026 11w ago | 8-K | $0.5289 $0.5189 | ▲ +1.89% | ▲ +1.84% | $0.1530 (+71.07%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.4754 $0.4629 | ▼ −2.63% | ▼ −3.06% | $0.1530 (−67.82%) |
Jun 8, 2026 20w ago | 8-K | $0.4556 $0.4433 | ▲ +2.70% | ▲ +5.11% | $0.1530 (+66.42%) |
Jun 1, 2026 21w ago | 8-K | $0.5200 $0.4560 | ▼ −12.31% | ▼ −9.34% | $0.1530 (−70.58%) |
May 15, 2026 23w ago | 8-K | $0.5040 $0.4900 | ▼ −2.78% | ▼ −3.74% | $0.1530 (−69.64%) |
May 15, 2026 23w ago | Press Release | $0.5040 $0.4900 | ▼ −2.78% | ▼ −3.74% | $0.1530 (−69.64%) |
May 11, 2026 24w ago | 8-K | $0.5300 $0.5200 | ▼ −1.89% | ▼ −1.96% | $0.1530 (−71.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers